|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US3662333A
(en)
|
1970-09-08 |
1972-05-09 |
Bendix Corp |
Hydraulic accumulator charge detector and indicating system
|
|
FR2413974A1
(fr)
|
1978-01-06 |
1979-08-03 |
David Bernard |
Sechoir pour feuilles imprimees par serigraphie
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
JPS62129297A
(ja)
|
1985-08-09 |
1987-06-11 |
Toyo Jozo Co Ltd |
カルシトニン遺伝子関連ペプチド誘導体
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5047335A
(en)
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
WO1990007936A1
(en)
|
1989-01-23 |
1990-07-26 |
Chiron Corporation |
Recombinant therapies for infection and hyperproliferative disorders
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
DE69034078T2
(de)
|
1989-03-21 |
2004-04-01 |
Vical, Inc., San Diego |
Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US6673776B1
(en)
|
1989-03-21 |
2004-01-06 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
|
|
DK0479909T3
(da)
|
1989-06-29 |
1997-04-07 |
Medarex Inc |
Bispecifikke reagenser til AIDS-behandling
|
|
CA2020786A1
(en)
|
1989-07-10 |
1991-01-11 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and essential hypertension and related disorders
|
|
EP0487587A1
(en)
|
1989-08-18 |
1992-06-03 |
Chiron Corporation |
Recombinant retroviruses delivering vector constructs to target cells
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
NZ237464A
(en)
|
1990-03-21 |
1995-02-24 |
Depotech Corp |
Liposomes with at least two separate chambers encapsulating two separate biologically active substances
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
DE69127627T2
(de)
|
1990-08-29 |
1998-02-19 |
Genpharm Int |
Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
|
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
|
US5278299A
(en)
|
1991-03-18 |
1994-01-11 |
Scripps Clinic And Research Foundation |
Method and composition for synthesizing sialylated glycosyl compounds
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
DE69233254T2
(de)
|
1991-06-14 |
2004-09-16 |
Genentech, Inc., South San Francisco |
Humanisierter Heregulin Antikörper
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
|
ATE237694T1
(de)
|
1991-08-20 |
2003-05-15 |
Us Gov Health & Human Serv |
Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
|
|
CA2078539C
(en)
|
1991-09-18 |
2005-08-02 |
Kenya Shitara |
Process for producing humanized chimera antibody
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
CA2119930C
(en)
|
1991-09-23 |
2002-10-01 |
Hendricus R. J. M. Hoogenboom |
Production of chimeric antibodies - a combinatorial approach
|
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
|
AU3144193A
(en)
|
1991-11-21 |
1993-06-15 |
Board Of Trustees Of The Leland Stanford Junior University |
Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
|
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
JPH07507689A
(ja)
|
1992-06-08 |
1995-08-31 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
特定組織のターゲティング方法及び組成物
|
|
CA2137361A1
(en)
|
1992-06-10 |
1993-12-23 |
W. French Anderson |
Vector particles resistant to inactivation by human serum
|
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
|
ATE149570T1
(de)
|
1992-08-17 |
1997-03-15 |
Genentech Inc |
Bispezifische immunoadhesine
|
|
US6210671B1
(en)
|
1992-12-01 |
2001-04-03 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with L-selectin
|
|
WO1994012649A2
(en)
|
1992-12-03 |
1994-06-09 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
WO1994021665A1
(en)
|
1993-03-24 |
1994-09-29 |
Amylin Pharmaceuticals, Inc. |
Cloned receptors and methods for screening
|
|
DE69431750T2
(de)
|
1993-04-22 |
2003-04-03 |
Skyepharma Inc., San Diego |
Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
|
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
|
WO1995000655A1
(en)
|
1993-06-24 |
1995-01-05 |
Mc Master University |
Adenovirus vectors for gene therapy
|
|
GB9316989D0
(en)
|
1993-08-16 |
1993-09-29 |
Lynxvale Ltd |
Binding molecules
|
|
EP0711829A3
(en)
|
1993-09-15 |
1997-07-09 |
Viagene Inc |
Recombinant alphavirus vector
|
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
|
DK0797676T3
(da)
|
1993-10-25 |
2006-04-18 |
Canji Inc |
Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf
|
|
BR9408072A
(pt)
|
1993-11-16 |
1997-08-12 |
Depotech Corp |
Vesículas com liberação controlada de ativos
|
|
JPH07196700A
(ja)
|
1994-01-06 |
1995-08-01 |
Sando Yakuhin Kk |
抗カルシトニン抗体及びその作製方法、並びに該抗体を用いたカルシトニンの測定方法
|
|
US6436908B1
(en)
|
1995-05-30 |
2002-08-20 |
Duke University |
Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
|
|
ES2297831T3
(es)
|
1994-05-09 |
2008-05-01 |
Oxford Biomedica (Uk) Limited |
Vectores retroviricos que presentan una tasa de recombinacion reducida.
|
|
WO1996005221A1
(en)
|
1994-08-16 |
1996-02-22 |
Human Genome Sciences, Inc. |
Calcitonin receptor
|
|
WO1996017072A2
(en)
|
1994-11-30 |
1996-06-06 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
|
FR2732222B1
(fr)
|
1995-03-28 |
1997-04-25 |
Oreal |
Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
|
|
FR2732221B1
(fr)
|
1995-03-28 |
1997-04-25 |
Oreal |
Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
|
|
FR2732220B1
(fr)
|
1995-03-28 |
1997-04-25 |
Oreal |
Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
|
|
FR2732598B1
(fr)
|
1995-04-10 |
1997-05-09 |
Oreal |
Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
|
|
EP0737471A3
(fr)
|
1995-04-10 |
2000-12-06 |
L'oreal |
Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
|
|
KR100654645B1
(ko)
|
1995-04-27 |
2007-04-04 |
아브게닉스, 인크. |
면역화된 제노마우스 유래의 인간 항체
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
EP0851759A4
(en)
|
1995-09-05 |
2000-12-06 |
Smithkline Beecham Corp |
COMPOUNDS AND RELATED METHODS
|
|
WO1997041223A1
(en)
|
1996-04-15 |
1997-11-06 |
The University Of Miami |
Molecular clone of cgrp receptor component protein and uses thereof
|
|
ATE424463T1
(de)
|
1996-05-06 |
2009-03-15 |
Oxford Biomedica Ltd |
Rekombinationsunfähige retrovirale vektoren
|
|
US5746694A
(en)
|
1996-05-16 |
1998-05-05 |
Wilk; Peter J. |
Endoscope biopsy channel liner and associated method
|
|
WO1998003534A1
(en)
|
1996-07-23 |
1998-01-29 |
Smithkline Beecham Corporation |
Calcitonin gene-related peptide receptor component factor (houdc44)
|
|
US6586458B1
(en)
|
1996-08-16 |
2003-07-01 |
Pozen Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
|
WO1998009630A1
(en)
|
1996-09-09 |
1998-03-12 |
Smithkline Beecham Corporation |
Compounds and methods
|
|
ATE266673T1
(de)
|
1996-09-10 |
2004-05-15 |
Boehringer Ingelheim Pharma |
Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
|
|
WO1998056779A1
(en)
|
1997-06-13 |
1998-12-17 |
Smithkline Beecham Corporation |
4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
|
|
US20030069231A1
(en)
|
1999-10-12 |
2003-04-10 |
Klaus Rudolf |
Modified aminoacids, pharmaceuticals containing these compounds and method for their production
|
|
WO1999018792A1
(en)
|
1997-10-10 |
1999-04-22 |
Johns Hopkins University |
Gene delivery compositions and methods
|
|
SE9704770D0
(sv)
|
1997-12-19 |
1997-12-19 |
Astra Ab |
New use
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
GB9809839D0
(en)
|
1998-05-09 |
1998-07-08 |
Glaxo Group Ltd |
Antibody
|
|
JP2002525371A
(ja)
|
1998-09-30 |
2002-08-13 |
メルク シャープ エンド ドーム リミテッド |
Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP1031350A1
(en)
|
1999-02-23 |
2000-08-30 |
Warner-Lambert Company |
Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
|
|
US6313097B1
(en)
|
1999-03-02 |
2001-11-06 |
Boehringer Ingelheim Pharma Kg |
Antagonists of calcitonin gene-related peptide
|
|
WO2000053211A2
(en)
|
1999-03-09 |
2000-09-14 |
University Of Southern California |
Method of promoting myocyte proliferation and myocardial tissue repair
|
|
US6521609B1
(en)
|
1999-08-10 |
2003-02-18 |
Boehringer Ingelheim Pharma Kg |
Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
|
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
|
US20020162125A1
(en)
|
2001-03-06 |
2002-10-31 |
Anne-Marie Salmon |
Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
|
|
ATE453661T1
(de)
|
2001-09-27 |
2010-01-15 |
Merck & Co Inc |
Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
|
|
US6767056B2
(en)
|
2002-01-14 |
2004-07-27 |
Shin Yeh Enterprise Co., Ltd. |
Settee with a foldable tray-support unit
|
|
DE60328195D1
(de)
|
2002-03-29 |
2009-08-13 |
Schering Corp |
Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
|
|
US7879991B2
(en)
|
2002-05-06 |
2011-02-01 |
Noxxon Pharma Ag |
CGRP binding nucleic acids
|
|
US20040110170A1
(en)
|
2002-05-18 |
2004-06-10 |
The Regents Of The University Of California |
Cloning and characterization of calcitonin gene related peptide receptors
|
|
US7345065B2
(en)
|
2002-05-21 |
2008-03-18 |
Allergan, Inc. |
Methods and compositions for alleviating pain
|
|
US7097467B2
(en)
|
2002-06-03 |
2006-08-29 |
Wan-Tien Chen |
Dustproof plate fixture for an electrical connector
|
|
BRPI0311812B8
(pt)
|
2002-06-05 |
2021-05-25 |
Bristol Myers Squibb Co |
antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
|
|
AU2003244817B2
(en)
|
2002-06-28 |
2010-08-26 |
Domantis Limited |
Antigen-binding immunoglobulin single variable domains and dual-specific constructs
|
|
DK1556020T3
(da)
|
2002-08-12 |
2009-06-22 |
Birkir Sveinsson |
Anvendelse af CGRP-antagonistforbindelser til behandling af psoriasis
|
|
MXPA05003502A
(es)
*
|
2002-10-08 |
2005-09-30 |
Rinat Neuroscience Corp |
Metodo para tratar dolor post-quirurgico al administrar un antagonista del factor de crecimiento de nervios y composiciones que contienen el mismo.
|
|
EP1578799B8
(en)
|
2002-12-02 |
2011-03-23 |
Amgen Fremont Inc. |
Antibodies directed to tumor necrosis factor and uses thereof
|
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
|
PT2263692T
(pt)
|
2002-12-24 |
2018-11-28 |
Rinat Neuroscience Corp |
Anticorpos anti-ngf e métodos de utilização dos mesmos
|
|
EP1605936B1
(en)
|
2003-03-14 |
2011-07-20 |
Merck Sharp & Dohme Corp. |
Aryl spirohydantoin cgrp receptor antagonists
|
|
EP1606286B1
(en)
|
2003-03-14 |
2011-05-11 |
Merck Sharp & Dohme Corp. |
Benodiazepine spirohydantoin cgrp receptor antagonists
|
|
JP4673295B2
(ja)
|
2003-03-14 |
2011-04-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
単環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
|
|
WO2004082602A2
(en)
|
2003-03-14 |
2004-09-30 |
Merck & Co. Inc. |
Carboxamide spirohydantoin cgrp receptor antagonists
|
|
WO2004082605A2
(en)
|
2003-03-14 |
2004-09-30 |
Merck & Co. Inc. |
Bicyclic anilide spirohydantoin cgrp receptor antagonists
|
|
JO2355B1
(en)
|
2003-04-15 |
2006-12-12 |
ميرك شارب اند دوم كوربوريشن |
Hereditary calcitonin polypeptide receptor antagonists
|
|
EP1615914B1
(en)
|
2003-04-15 |
2010-05-05 |
Merck Sharp & Dohme Corp. |
Cgrp receptor antagonists
|
|
WO2004097421A2
(en)
|
2003-04-29 |
2004-11-11 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
|
|
JP2007523870A
(ja)
|
2003-07-15 |
2007-08-23 |
メルク エンド カムパニー インコーポレーテッド |
ヒドロキシピリジンｃｇｒｐ受容体拮抗薬
|
|
US20080070239A1
(en)
|
2003-10-29 |
2008-03-20 |
University Of Rochester |
Detection of neureopeptides associated with pelvic pain disorders and uses thereof
|
|
DE102004015723A1
(de)
|
2004-03-29 |
2005-10-20 |
Boehringer Ingelheim Pharma |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
DE102004018794A1
(de)
|
2004-04-15 |
2005-10-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
US7279471B2
(en)
|
2004-04-15 |
2007-10-09 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
|
WO2005102322A1
(de)
|
2004-04-20 |
2005-11-03 |
Boehringer Ingelheim International Gmbh |
Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne
|
|
DE102004027912A1
(de)
|
2004-06-09 |
2005-12-29 |
Grünenthal GmbH |
Substituierte Cyclopenten-Verbindungen
|
|
US7384930B2
(en)
|
2004-11-03 |
2008-06-10 |
Bristol-Myers Squibb Company |
Constrained compounds as CGRP-receptor antagonists
|
|
TWI432196B
(zh)
|
2005-01-18 |
2014-04-01 |
Euro Celtique Sa |
內臟痛的治療
|
|
EP1770091A1
(de)
|
2005-09-29 |
2007-04-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
CA2619856A1
(en)
|
2005-08-25 |
2007-03-01 |
Wex Pharmaceuticals Inc. |
Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
|
|
ATE458491T1
(de)
|
2005-08-26 |
2010-03-15 |
Univ Leland Stanford Junior |
Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
|
|
JP2009508970A
(ja)
|
2005-09-21 |
2009-03-05 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
疼痛の局所造影および治療のためのシステム、組成物並びに方法
|
|
US8168592B2
(en)
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
|
RS20080200A
(sr)
|
2005-11-14 |
2009-07-15 |
Rinat Neuroscience Corp., |
Antagonistička antitela usmerena protiv kalcitonina, peptida povezanog sa genom, i postupak njihovog korišćenja
|
|
US8071770B2
(en)
|
2005-11-18 |
2011-12-06 |
Merck Sharp & Dohme Corp. |
Spirohydantoin aryl CGRP receptor antagonists
|
|
WO2007076336A1
(en)
*
|
2005-12-22 |
2007-07-05 |
Eli Lilly And Company |
Treatment of migraine with anti-cgrp antibodies
|
|
WO2008011190A1
(en)
|
2006-07-21 |
2008-01-24 |
Vertex Pharmaceuticals Incorporated |
Cgrp receptor antagonists
|
|
US8945505B2
(en)
|
2007-02-02 |
2015-02-03 |
Panaphix, Inc. |
Use of arsenic compounds for treatment of pain and inflammation
|
|
AU2008316988A1
(en)
|
2007-10-23 |
2009-04-30 |
Allergan, Inc. |
Methods of treating chronic neurogenic inflammation using modified clostridial toxins
|
|
US8293239B2
(en)
|
2008-03-04 |
2012-10-23 |
Pfizer Limited |
Methods of treating chronic pain
|
|
MX2010009724A
(es)
|
2008-03-04 |
2010-09-28 |
Pfizer Ltd |
Procedimientos de tratamiento del dolor inflamatorio-.
|
|
CA2721950A1
(en)
|
2008-04-25 |
2009-10-29 |
Nellix, Inc. |
Stent graft delivery system
|
|
WO2010006168A2
(en)
|
2008-07-09 |
2010-01-14 |
University Of Rochester |
Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
CA2771186C
(en)
*
|
2009-08-28 |
2018-01-02 |
Rinat Neuroscience Corporation |
Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
|
|
AR081434A1
(es)
|
2010-06-10 |
2012-08-29 |
Lilly Co Eli |
Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
|
|
US8669368B2
(en)
|
2010-10-12 |
2014-03-11 |
Bristol-Myers Squibb Company |
Process for the preparation of cycloheptapyridine CGRP receptor antagonists
|
|
RS58621B1
(sr)
|
2011-05-20 |
2019-05-31 |
Alderbio Holdings Llc |
Anti-cgrp kompozicije i njihova upotreba
|
|
CA2837000C
(en)
*
|
2011-05-20 |
2021-09-14 |
Alderbio Holdings Llc |
High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as pichia pastoris
|
|
JP6189832B2
(ja)
|
2011-05-20 |
2017-08-30 |
アルダーバイオ・ホールディングズ・エルエルシー |
慢性および急性の下痢を治療または予防するための抗ｃｇｒｐ若しくは抗ｃｇｒｐ−ｒの抗体または抗体断片の使用
|
|
NZ732970A
(en)
|
2011-05-20 |
2022-08-26 |
H Lundbeck As |
Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
|
|
BR112014003841B1
(pt)
|
2011-08-19 |
2022-02-15 |
H. Lundbeck A/S |
Método para identificar uma célula hospedeira diploide de pichia pastoris que produz um anticorpo desejado com uma maior pureza
|
|
SG11201403769YA
(en)
|
2012-01-10 |
2014-07-30 |
Noxxon Pharma Ag |
Nucleic acids specifically binding cgrp
|
|
US8722060B2
(en)
|
2012-05-23 |
2014-05-13 |
William J. Binder |
Method of treating vertigo
|
|
EP3324376A1
(en)
|
2012-10-29 |
2018-05-23 |
NetEnt Product Services Ltd. |
Architecture for multi-player, multi-game, multi- table, multi-operator & multi-jurisdiction live casino gaming
|
|
CN105121652B
(zh)
|
2013-03-15 |
2020-07-28 |
奥尔德生物制药公司 |
用于在酵母和其它转化细胞中高产量表达多肽的温度变动法
|
|
JP6466397B2
(ja)
|
2013-03-15 |
2019-02-06 |
アルダー・バイオファーマシューティカルズ・インコーポレーテッド |
抗原特異的ｂ細胞の同定及び単離ならびに所望の抗原に対する抗体作製のプロトコール
|
|
TWI712419B
(zh)
|
2013-07-03 |
2020-12-11 |
美商艾爾德生物製藥股份有限公司 |
使用抗ｃｇｒｐ抗體之葡萄糖代謝的調節
|
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
|
KR102274964B1
(ko)
|
2014-03-21 |
2021-07-09 |
테바 파마슈티컬스 인터내셔널 게엠베하 |
칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
|
|
CA2960756C
(en)
|
2014-09-15 |
2023-08-01 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
|
AR104847A1
(es)
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
MX2018003713A
(es)
|
2015-09-24 |
2018-08-15 |
Teva Pharmaceuticals Int Gmbh |
Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
|
|
US20180111984A1
(en)
|
2016-09-23 |
2018-04-26 |
Teva Pharmaceuticals International Gmbh |
Treating cluster headache
|
|
FI3515937T3
(fi)
|
2016-09-23 |
2026-02-11 |
Teva Pharmaceuticals Int Gmbh |
Refraktaarisen migreenin hoito
|
|
US20210340230A1
(en)
|
2018-08-22 |
2021-11-04 |
Eli Lilly And Company |
Anti-CGRP Antibodies For Treatment-Resistant Patients
|